Precision Medicine in Central Nervous System Drug Development

Dr. Daniel Klamer, has more than 15 years of experience in neuroscience and the orphan disease space, with acquisition, partnering and R&D experience in Europe and the U.S. Prior to Anavex, he worked at Retrophin and Neurosearch Sweden. At Neurosearch Sweden, Dr. Klamer led and evaluated multiple discovery-phase neuropharmacological research products with an emphasis on strategic evaluation of preclinical and clinical development.

Dr. Klamer earned his Ph.D. in Pharmacology at The Sahlgrenska Academy at the University of Gothenburg, Sweden, his MBA at Fordham Gabelli School of Business, and his Post-Doctoral training at the Department of Psychiatry, Yale University School of Medicine. In addition, Dr. Klamer holds a position as an Associate Professor at the Department of Pharmacology at The Sahlgrenska Academy at the University of Gothenburg. Learn more.